Savient Reports Additional Positive Trial Data For Secondary Endpoints From Puricase(R) (Pegloticase) Phase 3 Studies

Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), announced additional positive results for secondary efficacy endpoints in the two replicate Phase 3 studies for Puricase(R)(pegloticase) for treatment-failure gout.

More: continued here

Filed under: Clinical Trials on February 7th, 2008